About

I am an award-winning writer, editor, photographer and designer with more than 30 years of experience in the media. After studying at the University of Leeds, then London and Anglia HEC, I moved to Canada in the 1980s and started out on the radio while also writing for various music and sports publications, and doing freelance photography. I then edited some magazines before working at a science organization, doing communications and editing publications in a programming language called LaTeX that was challenging but exciting.

Following that, I edited a newspaper, spent some time in the US, and then moved back to the UK where I edited a food B2B publication.
I’ve written, and taken photographs for, hundreds of publications around the world, as well as for books, album covers, DVDs, and shot coverage for documentaries. I’ve edited books, written nine of my own, and done redesigns for several publications. And now I’m writing about biotech, as well as creating videos and a weekly podcast.

I’ve done other things, like running an aquarium, teaching photography and drumming (not at the same time), and running football (soccer) refereeing courses.

In what spare time I have, I love spending time with my wife, son and dog, challenging hikes up the Scottish hills (and down again), playing and writing music, watching baseball and soccer, and collecting memorabilia and autographs.

Articles by Jim Cornall

Pixelgen Technologies emerges to advance single-cell spatial proteomics

Apogee Therapeutics raises $169M to tackle immunological and inflammatory disorders

PacBio and Boston Children’s Hospital to study genome to benefit patients

Step Pharma and Concr to partner on cancer treatment

BiVictriX identifies development lead for ADC cancer program

Scientists identify genetic variant causing ALS in some patients

ADVERTISEMENT

Rani Therapeutics reveals results from phase 1 osteoporosis study

FDA clears insulin pen medical device

INSPIRE launched to develop inhaled gene therapy for the treatment of lung cancer

Entact Bio launches with $81M to develop precision medicines

Avalon BioVentures to invest in early-stage biotech

New brain tumor subtypes discovery may help develop treatments for incurable brain cancer

ADVERTISEMENT